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Abstract. Limited evidence exists that humans mount a mutation-specific T cell 
response to epithelial cancers. We used a whole-exomic-sequencing-based 
approach to demonstrate that tumor-infiltrating lymphocytes (TIL) from a patient with 
metastatic cholangiocarcinoma contained CD4+ T helper 1 (TH1) cells recognizing a 
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mutation in erbb2 interacting protein (ERBB2IP) expressed by the cancer. After 
adoptive transfer of TIL containing about 25% mutation-specific polyfunctional TH1 
cells, the patient achieved a decrease in target lesions with prolonged stabilization of 
disease. Upon disease progression, the patient was retreated with a >95% pure 
population of mutation-reactive TH1 cells and again experienced tumor regression. 
These results provide evidence that a CD4+ T cell response against a mutated 
antigen can be harnessed to mediate regression of a metastatic epithelial cancer. 
 
T cell based cancer immunotherapy, the concept of utilizing T cells to cure cancer 
patients was until recently regarded with skepticism. One of the main conceptual 
problem is that, physiologically, T cells recognize and eliminate cells that express 
non-self proteins. These are not usually present in cancer cells that instead express 
so called “tumor-associated antigens”, which are self-antigens expressed at different 
levels in cancer versus normal cells [1,2]. There are immunological consequences of 
this feature: tumor-associated antigens are poor inducers of tumor-specific T cells 
that do not expand in patients or poorly recognized the tumor cells. A second 
consequence is that if and when tumor-associated antigen-specific T cells are 
efficiently produced (for example by engineering T cells with chimeric T cell receptor 
(TCR) specific for tumor-associated antigens), the T cells will not only target tumor 
but also normal cells with clinical outcome that might be extremely severe [3]. 
However, the concept that cancerous cells do not express immunogenic non-self 
antigens change after the demonstration that the genetic alterations present in 
cancers can lead to production of new immunogenic “ non-self” antigens that can be 
exploited to induce effective tumor-specific T cell response. T cells specific for these 
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tumor-specific neo-antigens were detected in melanoma and were suggested to be 
the cause of the high immunogenicity of this cancer. 
In this new paper, Tran et al., makes the very important demonstration that such “neo 
antigens” are present and immunogenic not only in melanoma but also in cancer of 
epithelial origin which account for 80% of all human cancers.  Furthermore, they not 
only demonstrated that T cell recognizing a mutated version of a tumor associated 
antigen can be detected in a patient with metastatic cholangiocarcinoma but also that 
these mutation-specific T cells unique to the patient’s cancer can be harnessed to 
mediate regression of a metastatic epithelial cancer.  
To demonstrate the presence of the mutation-specific T cells, the authors first used a 
leading-edge whole-exomic sequencing based approach to identify mutated 
candidate epitopes expressed on lung metastases of a patient with bile duct cancer 
not responsive to standard chemotherapy. The 26 detected mutated sequences were 
expressed on autologous antigen presenting cells using constructed libraries of 
minigenes encoding the mutated sequences. They then tested whether the patient’s 
tumor-infiltrating lymphocytes (TIL) recognized any of these mutations and 
demonstrated that T cells infiltrating the patient’s tumor comprised of T cells that 
recognized only a mutated version of a ERBB2-interacting protein (ERBB2IP) but 
were unresponsive to the wild type non-mutated ERBB2IP. These mutations-specific 
T cells were CD4 cells, HLA-DQB1*0601 restricted, recognized a minimal epitope 
composed of 13 amino acids and seemed to be of mono-oligoclonal origin since they 
were characterized for a very restricted TCR usage. Direct evidences that these 
mutation-specific T cells can be exploited for therapeutic purpose were obtained by 
showing that adoptive cell transfer of a large quantity (42.4 billion) of the expanded 
TIL, of which about 25% were CD4+ ERBB2IP mutation-reactive T lymphocytes 
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caused tumor regression and disease stabilization for approximately one year.  This 
clinical efficacy was confirmed after a second round of adoptive T cell therapy in 
which 95% of the transferred cells were Vβ22+ ERBB2IP mutation-reactive TH1 cells 
that caused an accelerated tumor regression. 
Therefore, by demonstrating that mutations present in epithelial tumors produced 
new antigens able to induce T cells that recognize the patient-specific mutated 
protein, Tran et al bring to the forefront an alternative strategy to generate T cells for 
adoptive cell therapy and treat patients with common epithelial cancers, where there 
is a low frequency of tumor-reactive T cells. The results presented in this study are 
also encouraging as CD4+ TH1 cells, other than CD8 CTL, can confer clinical benefit 
in targeting cancer.  
Targeting sporadic or driver mutations unique to a patient’s individual cancer with 
mutation-reactive T cells have also the advantage to cause minimal amount of “off-
target” reactivity (cross-reactivity) and thus avoiding the severe side effects that have 
been described in some recent cancer immunotherapy trials [4,5]. 
Despite the remarkable results, the data has been obtained from a single patient and 
the feasibility of such method have to be evaluated in more patients with different 
epithelial cancers to analyze the extent to which tumor mutations can be targeted by 
adoptive T cell therapy. Furthermore, the approach described in this report is 
perhaps limited to cancers where there are few mutations, as screening hundreds of 
mutations for immunogenicity is technically challenging with current technology and 
there is also the risk that an already genetically unstable tumor might simply escape 
immune attack via down-regulation of the target protein. There have been evidence 
in human studies suggesting that effective immunotherapy might lead to cancer 
immunoediting [6,7]. Given the heterogeneity of majority of cancers, it is difficult to 
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predict if targeting a single mutation epitope might result in durable tumor control or 
selection of immunoresistant tumor variants that might accelerate tumor progression 
[8]. Nevertheless, the authors commented that “mapping of the mutational landscape 
of human cancer is occurring at rapid pace but clinical strategies to exploit such 
knowledge for clinical benefit remains to be realized”; and perhaps in the near future 
it might be possible to apply multi-epitope-based cancer immunotherapies in the 
clinic. 
This pioneering work opens the new exciting possibility to develop real personalized 
immune based targeted therapy for many different cancers. Sequences of proteins 
expressed by tumors could be used to detect mutations or also the presence of other 
“non-self proteins” like for example viral antigens, that should be highly represented 
in hepatitis B virus (HBV)-related HCC (where a high frequency of HBV-DNA 
integration is known to occur) [9], and target them with T cells expanded from the 
tumors or engineered to express specific T cell receptors [10]. 
The experimental framework to translate such knowledge in new therapy has been 
provided. The realization of clinical benefits for cancer patients might not be such a 
distant reality.   
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Figure legend 
Fig. 1. A schematic of identification of TIL that recognize patient-specific 
mutation in a patient with epithelial cancer, followed by treatment of patient 
using adoptive cell therapy with TIL containing Vβ22+ ERBB2IP mutation-
reactive T cells.  
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